Completed PHASE1 INTERVENTIONAL NCT00394446

Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors

Phase I Open Label, Dose Escalating, Multiple Dose Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, and Pharmacokinetics of MPC-6827 Administered IV Weekly X 3, Repeated Every 28 Days, in Subjects With Refractory Solid Tumors.

Sponsor: Myrexis Inc.

Conditions Refractory Solid Tumors

Interventions MPC-6827

Updated 7 times since 2017 Last updated: Feb 11, 2008 Started: Mar 31, 2005 Primary completion: Apr 30, 2007 Completion: Feb 29, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Refractory Solid Tumors and is currently completed. Myrexis Inc. leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE1
Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Myrexis Inc.

Data source: Myrexis Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States
• Salt Lake City, United States